Push for obesity drug coverage hits major roadblock
Few medications have made the kind of dramatic entrance to the public sphere that semaglutide (GLP-1) and tirzepatide…
Roche signs biggest-ever obesity drug deal
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this…
Hikma races to launch generic versions of blockbuster obesity drugs
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this…
Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash
The obesity drugs currently available address a broad swath of patients who struggle to manage their weight. While…
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations…
Obesity drugs Ozempic and Wegovy included in US price-cut talks
Unlock the White House Watch newsletter for free Your guide to what the 2024 US election means for…
58 medical experts propose to overhaul obesity diagnosis and treatment
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms…